• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Lifshitz Law PLLC Announces Investigations of HCCI, PRDS, NLTX, CCF

    7/22/23 8:07:00 PM ET
    $CCF
    $HCCI
    $NLTX
    $PRDS
    Building Products
    Consumer Discretionary
    Miscellaneous
    Industrials
    Get the next $CCF alert in real time by email

    NEW YORK, July 22, 2023 (GLOBE NEWSWIRE) --

    Heritage-Crystal Clean, Inc. (NASDAQ:HCCI)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of HCCI to an investment affiliate of J.F. Lehman & Company for $45.50 per share in cash for each share of HCCI common stock owned.

    If you are a HCCI investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    Pardes Biosciences, Inc. (NASDAQ:PRDS)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of PRDS to MediPacific, Inc. for a price per share of not less than $2.02 in cash, an additional cash amount of not more than $0.17 per share at closing, and one non-tradeable contingent value right for each share of PRDS common stock owned.

    If you are a PRDS investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    Neoleukin Therapeutics, Inc. (NASDAQ:NLTX)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of NLTX and Neurogene Inc. Under the terms of the proposed merger, NLTX will issue to pre-merger Neurogene Inc. stockholders shares of NLTX common stock as merger consideration in exchange for the cancellation of shares of capital stock of Neurogene Inc. and NLTX stockholders will be issued non-tradeable contingent value rights. Following the merger, pre-merger NLTX stockholders are expected to own approximately 16% of the combined company.

    If you are a NLTX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    Chase Corporation (NYSE:CCF)

    Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of CCF to an affiliate of investment funds managed by KKR for $127.50 per share in cash for each share of CCF common stock owned.

    If you are a CCF investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

    ATTORNEY ADVERTISING.© 2023 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

    Contact:

    Joshua M. Lifshitz, Esq.

    Lifshitz Law PLLC

    Phone: 516-493-9780

    Facsimile: 516-280-7376

    Email: [email protected]



    Get the next $CCF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CCF
    $HCCI
    $NLTX
    $PRDS

    CompanyDatePrice TargetRatingAnalyst
    Pardes Biosciences Inc.
    $PRDS
    7/18/2023Mkt Outperform → Mkt Perform
    JMP Securities
    Heritage-Crystal Clean Inc.
    $HCCI
    4/18/2023$42.00Buy
    Truist
    Heritage-Crystal Clean Inc.
    $HCCI
    1/11/2023$40.00Buy
    DA Davidson
    Pardes Biosciences Inc.
    $PRDS
    3/15/2022Outperform
    SVB Leerink
    Neoleukin Therapeutics Inc.
    $NLTX
    3/2/2022$30.00 → $25.00Overweight
    Piper Sandler
    Pardes Biosciences Inc.
    $PRDS
    1/18/2022$25.00Buy
    Jefferies
    Heritage-Crystal Clean Inc.
    $HCCI
    10/22/2021$34.00 → $39.00Buy
    Needham
    Neoleukin Therapeutics Inc.
    $NLTX
    8/6/2021$30.00Overweight
    Piper Sandler
    More analyst ratings

    $CCF
    $HCCI
    $NLTX
    $PRDS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Neoleukin Therapeutics Inc.

      SC 13G - Neurogene Inc. (0001404644) (Subject)

      2/14/24 6:05:00 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Neoleukin Therapeutics Inc. (Amendment)

      SC 13G/A - Neurogene Inc. (0001404644) (Subject)

      2/14/24 4:37:55 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Neoleukin Therapeutics Inc. (Amendment)

      SC 13G/A - Neurogene Inc. (0001404644) (Subject)

      2/14/24 4:26:22 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CCF
    $HCCI
    $NLTX
    $PRDS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Woods Robert Keith

      4 - Neurogene Inc. (0001404644) (Issuer)

      1/18/24 7:01:01 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Palekar Rohan

      4 - Neurogene Inc. (0001404644) (Issuer)

      1/18/24 6:58:27 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Noonberg Sarah B.

      4 - Neurogene Inc. (0001404644) (Issuer)

      1/18/24 6:56:12 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CCF
    $HCCI
    $NLTX
    $PRDS
    Financials

    Live finance-specific insights

    See more
    • Heritage-Crystal Clean, Inc. to Release 2023 Second Quarter Financial Results

      Heritage-Crystal Clean, Inc. (NASDAQ:HCCI) plans to release its financial results for the second quarter of 2023, which ended June 30, 2023, after the market close on Wednesday, August 9, 2023. As previously disclosed in a separate press release issued on July 19, 2023, the Company announced that it has entered into a definitive merger agreement to be acquired by an investment affiliate of J.F. Lehman & Company ("JFLCO"), a leading private equity investment firm focused on the aerospace, defense, maritime and environmental sectors, in an all-cash transaction that values Crystal Clean at approximately $1.2 billion. Due to the pending transaction with J.F. Lehman, the Company will not be ho

      7/28/23 5:00:00 PM ET
      $HCCI
      Miscellaneous
      Industrials
    • Neurogene and Neoleukin Announce Definitive Merger Agreement

      Proposed merger to create Nasdaq-listed biotech company focused on advancing Neurogene's differentiated portfolio of genetic medicines for complex neurological diseases Combined company is expected to have a cash balance of approximately $200 million at close, including approximately $95 million from concurrent private financing by Neurogene's new and existing investors Cash expected to fund combined company into 2H:26 and through multiple catalysts, including preliminary data in 4Q:24 and additional data in 2H:25 from a Phase 1/2 clinical trial in Rett syndrome Companies to host conference call today at 8:30 am ET NEW YORK and SEATTLE, July 18, 2023 (GLOBE NEWSWIRE) -- Neurogene Inc.,

      7/18/23 6:30:00 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heritage-Crystal Clean, Inc. to Hold 2023 First Quarter Conference Call

      Heritage-Crystal Clean, Inc. (NASDAQ:HCCI) plans to release its financial results for the first quarter of 2023, which ended March 31, 2023, after the market close on Tuesday, May 9, 2023. The company will host a conference call on Wednesday, May 10, 2023 at 9:00 AM Central Time, during which management will give a presentation focusing on the Company's operations and financial results. Interested parties can listen to the audio webcast available through our company website, http://www.crystal-clean.com/investor-relations/, and can participate on the call by dialing (888) 440-4149. After dialing the number, you will be required to provide the following passcode before being joined to the

      4/25/23 5:30:00 PM ET
      $HCCI
      Miscellaneous
      Industrials

    $CCF
    $HCCI
    $NLTX
    $PRDS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Inogen Names Michael Bourque as New Chief Financial Officer

      Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Michael Bourque as Chief Financial Officer, effective March 4, 2024. Mr. Bourque has served as Treasurer and Chief Financial Officer of Chase Corporation (NYSE:CCF) now owned by KKR & Co. Inc. He succeeds Interim Chief Financial Officer Mike Sergesketter, who will remain in an advisory role during the transition. Mr. Bourque has served as Chief Financial Officer and Treasurer of Chase Corporation since 2021. He also served as Chief Financial Officer of Keystone Dental, Senior Vice President, Chief Financial Officer and Treasu

      1/24/24 4:00:00 PM ET
      $CCF
      $INGN
      Building Products
      Consumer Discretionary
      Industrial Specialties
      Health Care
    • Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split

      SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" or the "Company" (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors ("Board") has approved a reverse stock split of the Company's outstanding shares of common stock at a ratio of 1-for-4. The reverse stock split will become effective at 12:02 a.m., Eastern Time on December 18, 2023. The Company's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Global Market on December 19, 2023, under the new name Neurogene Inc. and under the new symbo

      12/14/23 7:00:00 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chase Corporation Announces Completion of Acquisition by KKR and Welcomes Lance Reisman as Chairman of the Board of Directors

      Chase Corporation ("Chase" or the "Company"), a leading global manufacturer of protective materials for high-reliability applications across diverse market sectors, today announced the successful completion of its acquisition by affiliates of KKR, a leading global investment firm, for $127.50 per share. As a result of the completion of the transaction, Chase common stock has ceased trading and will no longer be listed on the NYSE American. "Today represents an important milestone for Chase in our journey to better serve our customers through strategic growth and innovation," said Adam Chase, President and Chief Executive Officer of Chase. "From the beginning, KKR was a strong cultural fit

      11/15/23 9:23:00 AM ET
      $CCF
      $KKR
      Building Products
      Consumer Discretionary
      Investment Managers
      Finance

    $CCF
    $HCCI
    $NLTX
    $PRDS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Pardes Biosciences downgraded by JMP Securities

      JMP Securities downgraded Pardes Biosciences from Mkt Outperform to Mkt Perform

      7/18/23 7:42:34 AM ET
      $PRDS
      Medicinal Chemicals and Botanical Products
      Health Care
    • Truist initiated coverage on Heritage-Crystal Clean with a new price target

      Truist initiated coverage of Heritage-Crystal Clean with a rating of Buy and set a new price target of $42.00

      4/18/23 7:18:49 AM ET
      $HCCI
      Miscellaneous
      Industrials
    • DA Davidson initiated coverage on Heritage-Crystal Clean with a new price target

      DA Davidson initiated coverage of Heritage-Crystal Clean with a rating of Buy and set a new price target of $40.00

      1/11/23 7:44:46 AM ET
      $HCCI
      Miscellaneous
      Industrials

    $CCF
    $HCCI
    $NLTX
    $PRDS
    SEC Filings

    See more
    • SEC Form 144 filed by Neoleukin Therapeutics Inc.

      144 - Neurogene Inc. (0001404644) (Subject)

      2/9/24 4:35:58 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neoleukin Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Neurogene Inc. (0001404644) (Filer)

      1/5/24 7:11:07 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neoleukin Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Shareholder Director Nominations, Regulation FD Disclosure

      8-K - Neurogene Inc. (0001404644) (Filer)

      12/19/23 7:31:02 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CCF
    $HCCI
    $NLTX
    $PRDS
    Leadership Updates

    Live Leadership Updates

    See more
    • Inogen Names Michael Bourque as New Chief Financial Officer

      Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Michael Bourque as Chief Financial Officer, effective March 4, 2024. Mr. Bourque has served as Treasurer and Chief Financial Officer of Chase Corporation (NYSE:CCF) now owned by KKR & Co. Inc. He succeeds Interim Chief Financial Officer Mike Sergesketter, who will remain in an advisory role during the transition. Mr. Bourque has served as Chief Financial Officer and Treasurer of Chase Corporation since 2021. He also served as Chief Financial Officer of Keystone Dental, Senior Vice President, Chief Financial Officer and Treasu

      1/24/24 4:00:00 PM ET
      $CCF
      $INGN
      Building Products
      Consumer Discretionary
      Industrial Specialties
      Health Care
    • Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition

      SEATTLE, March 08, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it has engaged SVB Securities to assist in reviewing strategic alternatives for the Company with the goal of maximizing shareholder value. Such alternatives may include a sale, merger, divestiture of assets, licensing or other strategic transaction. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive te

      3/8/23 5:00:00 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

      Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB. Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D. "I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board," said Dr. Walter Strapps, co-founder and CEO of Carver. "Along with Dr. Myhrvold, these scientific leaders will help us shape our pipeline and advance our programs into the clinic." Uri Lopatin, M.D. Dr. Lopatin is a serial biotech entrepreneur who founde

      1/17/23 7:00:00 AM ET
      $ASMB
      $PRDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products